Pharma& Schweiz founders Elmar Zagler (L) and Frank Rotmann
Facing Chapter 11, Clovis sells Rubraca rights to Swiss pharma for $70M
Clovis Oncology has found a buyer for its Rubraca rights as it goes through Chapter 11 proceedings.
The company is selling the rights to Switzerland …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
